First randomized trial of remdesivir suggests antiviral drug is not associated with significant clinical benefits, more research needed

Treatment with the antiviral drug remdesivir does not speed recovery from COVID-19 compared with placebo in hospitalized patients who are critically ill, according to the first randomized trial of its kind involving 237 adults from 10 hospitals in Wuhan, China.

Researchers help give robotic arms a steady hand for surgeries

Steady hands and uninterrupted, sharp vision are critical when performing surgery on delicate structures like the brain or hair-thin blood vessels. While surgical cameras have improved what surgeons see during operative procedures, the ‘steady hand’ remains to be enhanced — new surgical technologies, including sophisticated surgeon-guided robotic hands, cannot prevent accidental injuries when operating close to fragile tissue.

Stark disparities in COVID-19 hospitalization and death rates among New York

Researchers found that COVID-19 hospitalization and death rates varied across New York City boroughs. The Bronx — with the highest proportion of racial/ethnic minorities, the most poverty, and lowest educational attainment — had higher rates of hospitalization and death related to COVID-19 than all other boroughs. These rates were lowest in affluent Manhattan, comprised of a predominately white population. COVID-19 deaths per 100,000 persons was nearly two times greater in the Bronx than in Manhattan.